FOXO4-DRI

D-retro-inverso FOXO4 peptide that disrupts the FOXO4-p53 interaction in senescent cells. Studied as a targeted senolytic for clearing p21-positive cells to reduce senescence burden.

0 anonymous reports

Also known as:

foxo4 peptidesenolytic peptidefoxo4-p53 inhibitor

No reports found.

Community Q&A

What does FOXO4-DRI do?
Community accounts describe FOXO4-DRI as one of the most conceptually exciting senolytic peptides — targeting the mechanism by which senescent cells resist apoptosis. By disrupting the FOXO4-p53 binding that protects senescent cells from dying, FOXO4-DRI is described in accounts as triggering selective clearance of these cells. Confessions from users frame it as a longevity intervention targeting the root cause of cellular aging rather than downstream effects.
What have community members reported from FOXO4-DRI?
Community accounts on FOXO4-DRI are sparser and more cautious than most peptide categories — reflecting its experimental status. The most commonly described subjective effects: improved energy, reduced joint discomfort, and a general sense of physiological improvement over 4–8 week protocols. Accounts acknowledge difficulty attributing effects to FOXO4-DRI specifically, as most users run it alongside other longevity compounds. No consensus on optimal dosing exists in community reports.